plant lover, cookie monster, shoe fiend
20542 stories
·
19 followers

Man, 26, Drank Smoothie That Gave Him Dysentery for a Vaccine Trial - Business Insider

1 Share

On April 5, Jake Eberts drank a shot glass' worth of cloudy, salty liquid that he knew was infused with diarrhea-producing shigella bacteria. He also knew that bacteria would — in all likelihood — give him an excruciating case of dysentery. And it did.

Eberts was recently part of an 11-day inpatient vaccine trial at the University of Maryland, where he was one of 16 young, healthy adult participants given a drinkable shigella shot, which they all swallowed knowing it would likely make them violently ill.

It was all part of a tightly controlled process to test the vaccine candidate by "challenging" volunteers with a pathogen — some vaccinated and some not — and seeing how they fared.

Even though Eberts said what followed were "the worst eight hours of my life," he said he'd do it all over again, provided that he was paid (he earned more than $7,000 in this trial) and knew the research was being done for a good cause

"I don't want to make myself out to be Mother Teresa here — would not have done this for free. It's a big ask to ask someone to get dysentery," Eberts told Insider on the eve of his dismissal from the dysentery ward.

"The entire time, I was like, 'Wow, this is an awful disease.' And I just got really emotional, probably also because I was just delirious, about the thought of small children in the developing world dealing with this."

Why scientists need to test this vaccine on people like Eberts

jake drinking down buffer solution before ingesting shigella
@wokeglobaltimes

Every year, hundreds of thousands of children and older adults around the world die after contracting shigella. There is no approved vaccine against the bacteria, which is the second-leading cause of diarrhea death globally. (The No. 1 killer diarrhea is rotavirus, but there are multiple vaccines against it.)

People around the world get shigella the same way Eberts did: after sticking the bacteria in their mouth. Often, people are exposed by drinking contaminated water, eating food that has been prepared or handled by someone with dirty hands, or through coming into direct contact with an infected person's poop.

Scientists at the Institut Pasteur in France have been developing a vaccine against shigella for several years. It was tested initially in Israel and is now being tried out in several dozen consenting healthy adults in Maryland, including Eberts, as well as young kids in Kenya who may come in contact with the bacteria in their day-to-day lives. (They are not given shot glasses containing shigella.) 

If the current phase-two trials find the vaccine is both well-tolerated and effective at preventing severe disease, it could be tested in a large-scale real-world trial in hundreds of thousands of kids around the globe, a final regulatory move before the vaccine could be put on clinic shelves worldwide.

Dr. Wilbur Chen, who is running the trial at the University of Maryland, is hoping for 70% protection. If the vaccine doesn't demonstrate at least 50% protection against severe disease in his trial, "then I think then we will have a vaccine that really fails, unfortunately," Chen said, adding: "It's kind of a high bar."

'Never in my life have I felt so exhausted'

Eberts had a hunch that he was in the unlucky nonvaccinated placebo group, given that he didn't react in any noticeable way to his two injections. He also ended up with one of the worst cases of dysentery in this trial.

"If I did get the vaccine, that is really bad news for the vaccine," he said.

His illness started about 40 hours after he drank the shigella, when he woke up to cramps and some chills, feeling like he had a "stomach bug." His symptoms quickly progressed into fever, diarrhea, and bloody stool.

"I truly felt like I could not move," Eberts said, adding that getting up to go to the bathroom or get his vitals checked required a "Herculean effort."

"Every movement in the bathroom, to get up to wash my hands or to grab a paper towel, I would lie back down on the ground and just sit there for five minutes," he said.

Nurses began prescribing him many liters of rehydration solution, which he described as "sad Gatorade," a salty-sweet water designed to keep him functioning but without any yummy flavor or bright coloring.

He lied down under a pile of blankets, and his fever rose to 103 degrees Fahrenheit. After several hours, he was put on IV fluids and given the antibiotic ciprofloxacin. Within four hours, his condition started to improve, as he went from "death's door" to coherent, lucid, and able to walk and talk "with a little bit of effort."

"I was exhausted and felt miserable, but I didn't feel fear," he said. "I knew this is something I signed up for, and it will pass, and I'm not going to die or anything. But even if I had been just at home and had somehow come across this, I would've been terrified because it was just awful. And the deterioration was so rapid."

Participants were isolated and had to bleach the toilet after each use

People with shigellosis can infect others with the bacteria. That meant the study participants had to stay inside and eat alone during the entire 11- to 12-day study.

Going to the bathroom during the study was a multistep 15-minute event involving a special toilet "hat," a nurse, and bleach.

Every time Eberts had to relieve himself, he'd put the white hat (pictured below) over the brim of a toilet, do his business, cover it with a paper towel or biohazard bag, and cart it down the hallway for sample extraction. Once the nurses had taken what they needed from him, he'd pour the rest of his waste in a toilet, cover it with bleach, wait five minutes, and flush away.

When Eberts got really sick, the nurses rolled in a commode and did the sample processing for him.

This diligent feces and urine collection — painstaking though it may be — has an important role in discovering how well this vaccine works.

beds and bed pan
Left, the dorms where study participants stayed. Right, Eberts had to use this bonnet every time he went to the bathroom so that researchers could extract a sample from it and analyze his illness.  @wokeglobaltimes

Taking precise measurements from participants' blood, urine, and poo helps researchers like Chen learn exactly what kind of immune response the vaccine elicits.

Researchers can better gauge whether the vaccine lessens the burden of disease by analyzing the level of anti-shigella IgA antibodies a person is excreting, and determining the amount and type of cytokines circulating in their stool.

"It is a way for us to be able to learn about the mechanisms of protection," Chen said.

Eberts inspired others to sign up for vaccine 'challenges' on Twitter

Motivated by how awful the disease made him feel, Eberts raised more than $23,900 for The Water Project while in isolation. And his barrage of detailed tweets about the experience while in inpatient care inspired several dozen others to volunteer to take part in this style of vaccine research.

"I've been spending my career trying to tackle this, and it's always a challenge to try to find willing volunteers," Chen said, adding that within a few days of Jake's tweeting, the center had "20- or 30-some people that signed up with interest" in its trials.

shigella vaccine research study recruitment poster
The advertisement on Instagram that caught Eberts' eye.  @wokeglobaltimes

"He was just sharing from the heart, and I think people liked it," Chen said.

Now that the trial is over, and Eberts is allowed to go outside and touch grass again, he's looking forward to spending some time with his dog and enjoying a latte or two. ("There's no espresso machine" at the trial site, he said.) 

Eberts is ineligible for another shigella trial like this now that he's been exposed to the bacteria, but he said he would consider trying another vaccine "challenge" like it. Other trials are being run for dengue-fever, flu, and malaria vaccines.

"Some people go to soup kitchens to get their charity fix. This might be the way I do it," he said.

Read the whole story
sarcozona
2 hours ago
reply
Epiphyte City
Share this story
Delete

China offers diplomatic immunity in bid to host oceans treaty

1 Share
Read the whole story
sarcozona
1 day ago
reply
Epiphyte City
Share this story
Delete

How the EU made Viktor Orbán

1 Share
Read the whole story
sarcozona
2 days ago
reply
Epiphyte City
Share this story
Delete

Europe’s rearmament meets reality: the story of a failed frigate project

1 Share
Read the whole story
sarcozona
2 days ago
reply
Epiphyte City
Share this story
Delete

Illuminated in Orion

1 Share
NASA astronaut Christina Koch is illuminated by a screen inside the darkened Orion spacecraft on the third day of the agency's Artemis II mission. To the right of the image's center, CSA (Canadian Space Agency) astronaut Jeremy Hansen is seen in profile peering out of one of Orion's windows. Lights are turned off to avoid glare on the windows.

Read the whole story
sarcozona
5 days ago
reply
Epiphyte City
Share this story
Delete

I Wrote Research Funding Announcements for NIH for 22 Years. This Year They’ve Published 14

1 Share

For decades, the National Institutes of Health published between 650 and 850 Notices of Funding Opportunities each year. These announcements tell the research community which diseases need study, which populations are underserved, which scientific gaps need filling. They are how NIH directs resources toward problems that won’t get solved by waiting for whatever grant applications happen to arrive.

In 2024, NIH published 756 funding announcements.

In 2025, it published 120.

In 2026, as of March 15, it has published 14.

I spent 22 years as a program official at NIH writing these announcements. I know what they accomplish and what happens when they disappear. This essay is about what the data reveals and what it means for every disease, every research area, and every population that depends on NIH-funded research.

Figure 1. NIH NOFOs Published Over Time

A Notice of Funding Opportunity (NOFO) is how NIH tells researchers what the agency needs. It specifies a research problem, explains why it matters, describes the approach NIH is looking for, and sets aside dedicated funding to solve it.

NOFOs exist because not all research needs are obvious to individual investigators. When a new pathogen emerges. When clinical trials reveal an unexpected side effect that needs investigation. When one population experiences a disease at higher rates than others but nobody knows why. When a promising scientific approach exists but no one is applying it to a specific problem. These are moments when waiting for unsolicited grant applications is not enough.

Writing a NOFO was one of my primary responsibilities as a program official. When my institute identified a gap, I would work with scientific experts to define the problem precisely, determine what kind of research was needed, and draft an announcement that would attract the right investigators. The announcement would be reviewed by our advisory council, posted publicly, and researchers across the country would know: NIH has identified this as a priority and has set aside funding to address it.

This is scientific stewardship. It is not top-down control of what researchers can study. Investigators can always submit unsolicited proposals on any topic within an institute’s mission. But NOFOs allow program staff to actively direct resources toward problems that need attention rather than passively waiting to see what applications arrive.

And then it stopped.

I downloaded all available NOFO data from NIH’s historical records and grants.gov and analyzed every funding announcement published from 2012 through March 15, 2026. What I found was worse than anything reported in the media.

From 2012 through 2023, NIH published an average of just over 700 NOFOs per year. There was variation (a peak of 1,110 in 2017, a low of 535 in 2012), but the system was stable. Institutes identified research needs and issued announcements to address them. In 2024, that number was 756, still within the normal range.

Then the collapse began. By 2025, only 120 announcements were posted, an 84% decline. As of mid-March 2026, only 14 have been published. If the current pace continues, this year will see a 98% reduction from historical norms.

The decline is not limited to a few institutes. It is systemic. The National Cancer Institute, which historically published more NOFOs than any other institute, has gone nearly silent. The National Institute of Allergy and Infectious Diseases, responsible for pandemic preparedness and emerging disease response, has published almost nothing. Institutes focused on mental health, aging, drug abuse, environmental health, and rare diseases have all but stopped issuing targeted funding announcements.

This is not a temporary slowdown. It is a structural collapse.

Figure 2. NIH NOFOs Published by Each Institute/Center Over Time

The collapse began with a policy change. In recent guidance, NIH leadership announced an “overall reduction in number of NIH NOFOs.” The stated goal was to streamline funding opportunities and reduce redundancy.

At the same time, the approval process for NOFOs was fundamentally restructured. Previously, funding announcements were primarily reviewed and approved within individual institutes by scientific program staff and external advisory councils composed of researchers and public representatives. The process typically took weeks to a few months.

Under the new system, every NOFO must be approved by political appointees in the NIH director’s office and the Department of Health and Human Services before it can be posted. The approval process now takes a minimum of six months, and many announcements seem to be remaining in review indefinitely.

More recently, NOFOs must also be approved by the Office of Management and Budget. This adds another layer of political review to what was previously a scientific decision-making process. OMB now has effective veto power over which research priorities NIH can pursue.

Additionally, NIH stopped publishing funding announcements directly through its traditional NIH Guide for Grants and Contracts. Instead, all NOFOs must now be entered into grants.gov as “forecasts” and wait for approval before becoming active funding opportunities.

The effect of these changes is visible in the data. Institutes are still identifying research needs. Program staff are still writing announcements. But the announcements are not being approved. They sit in forecast limbo, written but never posted, planned but never executed.

This is where the data becomes particularly damning.

In 2025, NIH institutes entered 391 total funding announcements into grants.gov (they all start as forecasts). Only 120 of them were actually posted and opened for applications. That means 271 announcements (69% of what was planned) were written, reviewed internally, entered into the system, and then blocked at the final approval stage (they still appear as forecasted).

In 2026, so far institutes have forecasted 75 announcements, and only 14 have been posted. Sixty-one remain in limbo (81% of what was planned).

These are not ideas that were considered and rejected for scientific reasons. These are fully developed funding announcements that passed internal scientific review, were deemed important enough to allocate budget toward, and were ready to go. They are sitting in a bureaucratic queue waiting for political approval that, in most cases, never comes.

The forecast graveyard proves this is not about scientific prioritization or budget constraints. If it were, the announcements would not have been written and forecasted in the first place. This is about centralized control. About requiring that every research priority, every identified gap, every targeted funding decision be approved by political appointees rather than scientific program staff. And the result is paralysis.

Figure 3. NIH NOFOs in Grants.gov Under the New “Forecast” Policy

When NIH stops issuing targeted funding announcements, specific kinds of research become much harder to sustain.

Rare disease research suffers because individual investigators are unlikely to propose studies on conditions affecting small populations unless NIH signals it is a priority and has dedicated funding. Research on health disparities struggles for the same reason. Studies requiring particular methodologies, specific patient populations, or coordination across multiple sites all depend on NOFOs that describe exactly what NIH is looking for and commit resources to support it.

Emerging threats become harder to address quickly. When COVID-19 emerged, NIH issued emergency funding announcements within weeks. Those NOFOs allowed the agency to mobilize researchers rapidly toward specific problems: vaccine development, therapeutic testing, long-term effects, vulnerable populations. Without the ability to issue targeted calls, response to future health emergencies will be slower and less coordinated.

Innovation in underfunded areas stalls. There are always scientific approaches or technologies that show promise but have not yet attracted enough investigator interest to generate unsolicited applications. NOFOs can seed these areas by explicitly inviting proposals and providing startup funding. When announcements stop, these nascent fields often wither before they mature.

Scientific program staff lose the ability to steward their fields. Part of my job was watching for gaps, talking to researchers about unmet needs, and working with my institute to direct resources toward those problems. That function is being eliminated. What remains is passive grant processing: review whatever applications arrive and fund the highest-scoring proposals. That approach works for well-established research areas with active investigator communities. It fails for everything else.

The collapse of NIH funding announcements is part of a larger pattern I have documented in previous essays: restructuring the agency without congressional authorization.

Congress rejected proposals to consolidate NIH’s 27 institutes and centers. But if all institutes are restricted to processing generic unsolicited applications through the same centralized approval system, the functional distinction between them disappears. Why maintain 27 separate entities if none of them can independently set research priorities or direct resources toward identified gaps?

The NOFO collapse accomplishes administratively what could not be achieved legislatively. It strips institutes of the autonomy that made them distinct. It centralizes decision-making under political appointees. It eliminates the scientific stewardship function that program staff have exercised for decades. And it does all of this without a single congressional hearing or recorded vote.

This represents a redefinition of what NIH does. The agency is being transformed from an institution that actively identifies and addresses research needs into a passive funding mechanism that distributes money to whatever proposals happen to arrive. That transformation has profound implications for every disease that depends on NIH research, every population whose health needs are not currently being addressed by unsolicited grant applications, and every future health crisis that will require rapid, coordinated research response.

I spent 22 years identifying research gaps and writing announcements to fill them. When a new disease emerged, when a population was being overlooked, when a promising area needed resources, we could act. That is what scientific stewardship looks like. It is not perfect. It makes mistakes. It can be slow. But it represents accumulated expertise about what research is needed and how to direct resources toward it.

The data shows that function being eliminated in real time. Active direction of resources toward need has been replaced by passive waiting for whatever applications arrive. Scientific program staff exercising judgment about research priorities have been replaced by political appointees controlling every announcement.

The 151 announcements sitting in forecast limbo for 2025, and the 47 blocked so far in 2026, prove this is not happening because of lack of scientific need or budget constraints. The announcements were written. The problems were identified. The resources were allocated. What changed was who gets to decide whether those announcements become active funding opportunities.

This is not efficiency. This is not streamlining. This is the systematic elimination of scientific stewardship at the world’s largest biomedical research funder.

And most people have no idea it is happening.

This essay is part of an ongoing series reflecting on what I learned over more than two decades working inside the U.S. biomedical research enterprise. Each piece stands alone, but together they examine how science is shaped not only by ideas and funding, but by the structures that support or constrain them.

National Institutes of Health. (2025). Updates to finding NIH funding opportunities and information. https://grants.nih.gov/policy-and-compliance/implementation-of-new-initiatives-and-policies/updates-to-finding-nih-funding-opportunities-and-information

Kaiser, J. (2026, March 3). Delays in awards and funding calls worry NIH-funded researchers. Science. https://www.science.org/content/article/delays-grant-awards-and-funding-calls-worry-nih-researchers

NOFO data was compiled by the author from NIH Guide for Grants and Contracts historical archives and grants.gov records, downloaded March 15, 2026. Analysis covers all funding announcements published from 2012 through March 15, 2026.

Read the whole story
sarcozona
5 days ago
reply
Epiphyte City
Share this story
Delete
Next Page of Stories